)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Chimeric Therapeutics
Chimeric Therapeutics (CHM) investor relations material
Chimeric Therapeutics Investor presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investor presentation summary27 Jul, 2026
Investment highlights
Three Phase 1 clinical trials underway at six leading US centers under three FDA INDs.
Multiple clinical updates expected within the next six months.
Leadership team experienced in cell therapy clinical development.
First CDH17 CAR-T therapy in clinical trials, with robust patent portfolio.
Market cap approximately $3.1 million, share price at $0.036.
Clinical pipeline and progress
Two novel cell therapies in portfolio: CHM CDH17 CAR-T and CHM CORE-NK, each in clinical trials.
CHM CDH17 CAR-T is the first of its kind in clinical trials globally, with 14 patients treated and no safety issues to date.
CHM CORE-NK is an off-the-shelf allogeneic NK cell therapy, with positive Phase 1A results in AML and ongoing Phase 1B trials.
Manufacturing for CHM CDH17 has achieved 15/15 successful GMP-compliant runs.
Dose escalation and expansion ongoing for both programs, with first-line dosing underway in AML.
Clinical results and safety
CHM CDH17 CAR-T showed complete eradication of tumors in preclinical mouse models with no relapse.
In clinical trials, anti-tumor activity and tumor shrinkage observed, with no off-target effects or unexpected safety issues.
CHM CORE-NK achieved 15/25 complete responses in frontline AML patients, with no safety issues reported.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Chimeric Therapeutics
- Advancing three novel cell therapies in four Phase 1/1b trials with strong leadership and clinical progress.CHM
AGM Presentation 2024 - CDH17 CAR T therapy achieved 82% stable disease and durable cell persistence in GI cancers.CHMStudy update
- Major capital raising and share consolidation approved amid focus on governance and capital efficiency.CHMEGM 2026
- Reduced loss, increased cash, and major funding support ongoing oncology trial progress.CHMH2 2025
- Cell therapy trials advance with strong efficacy, safety, and key milestones expected in FY26.CHMNWR Virtual Healthcare Conference
- Loss widened on asset impairment; $8.4M raised, but going concern risk persists.CHMH1 2026
- Financial and clinical resolutions passed with strong support; risks and milestones addressed.CHMEGM 2025
- Promising early results and improved funding support ongoing clinical progress in cell therapies.CHMStatus Update
- Early clinical results show safety and disease control, with new funding fueling trial expansion.CHMNWR Virtual Healthcare Conference
Next Chimeric Therapeutics earnings date
H2 20265 Nov, 2026
Chimeric Therapeutics
Next Chimeric Therapeutics earnings date
H2 20265 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Chimeric Therapeutics Ltd is a biotechnology company focused on developing cell therapy treatments for cancer. The company specializes in chimeric antigen receptor T-cell (CAR-T) therapies, aiming to harness the immune system to target solid tumors and hematologic malignancies. The company is headquartered in Melbourne, Australia, and its shares are listed on the ASX.